Cardiovascular Complications of Sickle Cell Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In this research study, we are using heart imaging exams and blood testing, in order to gain an improved understanding of the pulmonary (lung) hypertension and cardiovascular (heart) complications that often occur in sickle cell patients. Information gathered from the healthy volunteers that participate in this study will be compared to information from the sickle cell patients in this study in order to help further our understanding.
| Condition | Intervention |
|---|---|
|
Sickle Cell Disease |
Procedure: MRI, Transthoracic Echocardiography, tonometry, EKG |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Cardiovascular Complications of Sickle Cell Disease |
- We plan to comprehensively and quantitatively characterize the cardiopulmonary complications of SCD and gain an improved understanding of the pathophysiology of pulmonary hypertension and diastolic dysfunction in patients with Sickle Cell Disease. [ Time Frame: 2013 ] [ Designated as safety issue: No ]
- To detect genome-wide gene expression and targeted genetic polymorphisms in SCD patients linked to a quantitative noninvasive-based PH phenotype. [ Time Frame: 2013 ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
We will study blood samples for chemicals related to sickle cell and heart and lung disease, and will be evaluating DNA for purposes of the study.
| Estimated Enrollment: | 220 |
| Study Start Date: | March 2009 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| Subjects with Sickle Cell Disease |
Procedure: MRI, Transthoracic Echocardiography, tonometry, EKG
Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
Other Names:
|
| Healthy Volunteers |
Procedure: MRI, Transthoracic Echocardiography, tonometry, EKG
Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
Other Names:
|
Detailed Description:
Cardiac magnetic resonance (CMR) has gained increasing clinical application in cardiopulmonary diseases. Due to its 3-dimensional nature, CMR is considered the gold-standard for quantifying left and right ventricular systolic function and size. Additionally, its high tissue contrast allows for a detailed characterization of myocardial tissue. Specifically, the use of techniques such as late gadolinium enhancement can be used to detect the presence of tiny amounts of myocardial scar. Other techniques have been shown to correlate strongly with myocardial iron content. Just as importantly, CMR perfusion imaging can accurately quantify myocardial blood flow and can provide tremendous insight into the function of the microcirculation. CMR's high spatial and temporal resolution, its 3-dimensional approach, its ability to characterize the tissue, and its ability to evaluate the micro- and macro-circulation make it a comprehensive technique for the evaluation of heart disease. Recently, one CMR study has already shown the presence of cardiac microvascular disease in a subset of adult sickle cell disease (SCD) patients in the absence of infarcted myocardium, myocardial iron overload, or coronary artery disease, increasing the evidence for the contribution of left heart disease to pulmonary hypertension (PH) development in these patients; unfortunately, strong conclusions could not be made because the study was underpowered. Thus, this proposal will leverage the advantages offered by CMR to better characterize and detect the PH and cardiopulmonary subphenotypes in the SCD patient population.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Subjects will be recruited from clinics at the University of Chicago as well as from the community via flyers posted at the University of Chicago and a web site posted on the University of Chicago Medical Center web site.
Inclusion Criteria:
- Patients must be 18+
- Patients who were diagnosed with SCD confirmed by high-pressure liquid chromatography or hemoglobin electrophoresis will be eligible for the study
- Only patients in stable condition will be included
- Patients receiving transfusions will not be excluded
Exclusion Criteria:
- Patients with vaso-occlusive crises or an episode of acute chest syndrome within the previous four weeks (after 4 weeks have passed, the patients may be re-evaluated for eligibility)
- Patients with high degree heart block; active, hemodynamically significant, ventricular arrhythmias; unstable coronary syndromes; history of myocardial infarction within 1 month of the study.
- Contraindications to gadolinium-enhanced magnetic resonance examination such as severe claustrophobia, Pacemaker, defibrillators, cerebral aneurysm clips, or neurostimulator.
- Pregnancy
- Patients with sinus node dysfunction
Contacts and Locations| Contact: Amit R Patel, M.D. | 773-702-1843 | amitpatel@uchicago.edu |
| United States, Illinois | |
| University of Chicago Medical Center | Recruiting |
| Chicago, Illinois, United States, 60430 | |
| Contact: Amit R Patel, M.D. (773) 702-1843 amitpatel@uchicago.edu | |
| Principal Investigator: Amit R Patel, M.D. | |
| Sub-Investigator: Joe G.N. Garcia, M.D. | |
| Sub-Investigator: Roberto M Lang, M.D. | |
| Sub-Investigator: Nicole Artz, M.D. | |
| Sub-Investigator: Roberto Machado, M.D. | |
| Sub-Investigator: Ankit A Desai, M.D. | |
| Principal Investigator: | Amit R Patel, M.D. | University of Chicago |
More Information
No publications provided
| Responsible Party: | Amit Patel, Asst Prof of Medicine, University of Chicago |
| ClinicalTrials.gov Identifier: | NCT01044901 History of Changes |
| Other Study ID Numbers: | 16653A |
| Study First Received: | January 6, 2010 |
| Last Updated: | July 11, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Chicago:
|
Sickle Cell Disease Cardiac magnetic resonance imaging Coronary Disease Pulmonary Hypertension |
Additional relevant MeSH terms:
|
Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia |
Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn |
ClinicalTrials.gov processed this record on May 19, 2013